PRESS RELEASE FROM NEUROPSYCHOPHARMACOLOGY (http://www.nature.com/npp)

For papers that will be published online on 16 February 2011

This press release is copyrighted to the journal *Neuropsychopharmacology*. Its use is granted only for journalists and news media receiving it directly from the Nature Publishing Group.

*** PLEASE DO NOT REDISTRIBUTE THIS DOCUMENT ***

EMBARGO:

1430 London time (GMT) / 0930 US Eastern time Wednesday 16 February 2230 Japanese time / 2330 Australian Eastern time Wednesday 17 February

Wire services' stories must always carry the embargo time at the head of each item, and may not be sent out more than 24 hours before that time.

Solely for the purpose of soliciting informed comment on this paper, you may show it to independent specialists - but you must ensure in advance that they understand and accept the embargo conditions.

This press release contains:

• Summaries of newsworthy papers:

Genetic basis for resilience

A chronic high-fat diet creates a need to overeat

A PDF of the paper mentioned on this release can be found in the Academic journals section of <u>http://press.nature.com</u>. Press contacts for the journals are listed at the end of this release.

Warning: This document, and the Academic Journal paper to which it refers, may contain information that is price sensitive (as legally defined, for example, in the UK Criminal Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in securities using information contained in this document or in advanced copies of *Nature*'s content may be guilty of insider trading under the US Securities Exchange Act of 1934.

PICTURES: While we are happy for images from *Neuropsychopharmacology* to be reproduced for the purposes of contemporaneous news reporting, you must also seek permission from the copyright holder (if named) or author of the research paper in question (if not).

HYPE: We take great care not to hype the papers mentioned on our press releases, but are sometimes accused of doing so. If you ever consider that a story has been hyped, please do not hesitate to contact us at <u>press@nature.com</u>, citing the specific example.

PLEASE CITE NEUROPSYCHOPHARMACOLOGY AND THE NEUROPSYCHOPHARMACOLOGY WEBSITE AS THE SOURCE OF THE FOLLOWING ITEM. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO <u>www.nature.com/npp/</u>

Genetic basis for resilience

DOI: 10.1038/NPP.2010.251

In homes where parents have substance abuse, mental health, or criminal problems, children with a common variant of a gene critical to reward systems in the brain seem to have better relationships with their parents than children without it. The research, published online this week in the journal *Neuropsychopharmacology*, could provide the genetic explanation for "resilience" in children in problematic households, showing evidence that opioids—natural chemicals in the brain—play a role in moderating social interactions in humans.

The mu-opioid receptor gene (OPRM1) receptor, which regulates endogenous opioids in the brain, has previously been associated with social behaviors in mice and rhesus macaques. William Copeland and colleagues assessed the OPRM1 receptor and parental interactions in 226 children between the ages of nine and 17 years old. Children from problematic households who had the OPRM1 gene variant reported fewer arguments and more enjoyable interactions with their parents than did children without this variant. However, no such association was found in children who came from stable homes.

Author contact:

William Copeland (Duke University Medical Center, Durham, NC, USA) Tel: +1 919 687 4686; E-mail: william.copeland@duke.edu

Editorial contact:

Diane Drexler (Neuropsychopharmacology, Nashville, TN, USA) Tel: +1 615 324 2371; E-mail: journal@acnp.org

A chronic high-fat diet creates a need to overeat

DOI: 10.1038/NPP.2011.4

Excessive consumption of good-tasting food by obese individuals may reflect an effort to mitigate deficits in the brain's reward centers, suggests a study published online this week in *Neuropsychopharmacology*. The findings suggest that blocking or reversing chemical alteration in certain genes associated with pleasure may be a useful approach to treating obesity.

Mu-opioid receptors (MORs) in the brain play an essential role in our ability to experience pleasure and reward, and are known to regulate the enjoyment received from consuming goodtasting food. Teresa Reyes and colleagues fed mice a consistently high-fat diet from weaning in order to induce obesity and found that it led to genetic modifications that decreased MOR expression in neural reward centers. The obese mice were also less sensitive to otherwise pleasurable experiences than lean control mice, suggesting they would have to consume more to experience the same effect.

Author contact:

Teresa Reyes (University of Pennsylvania School of Medicine, Philadelphia, PA, USA) Tel: +1 215 573 2991; E-mail: reyestm@mail.med.upenn.edu

Editorial contact:

Diane Drexler (Neuropsychopharmacology, Nashville, TN, USA) Tel: +1 615 324 2371; E-mail: journal@acnp.org

PRESS CONTACTS

For media inquiries relating to embargo policy for the Journal Neuropsychopharmacology:

Neda Afsarmanesh (Nature New York) Tel: +1 212 726 9231; E-mail: <u>n.afsarmanesh@natureny.com</u> Ruth Francis (*Nature* London) Tel: +44 20 7843 4562; E-mail: <u>r.francis@nature.com</u>

For media inquiries relating to the American College of Neuropsychopharmacology: Tel: +1 615 324 2360; E-mail: <u>acnp@acnp.org</u>

About Nature Publishing Group (NPG)

Nature Publishing Group is a division of Macmillan Publishers Ltd, dedicated to serving the academic and professional scientific and medical communities. NPG's flagship title, *Nature*, was first published in 1869. Other publications include *Nature* research journals, *Nature Reviews*, *Nature Clinical Practice* and a range of prestigious academic journals including society-owned publications. NPG also provides news content through *Nature News*. Scientific career information and free job postings are offered on *Naturejobs*.

NPG is a global company with principal offices in London and New York and offices in Basingstoke, Boston, Buenos Aires, Delhi, Hong Kong, Madrid, Melbourne, Munich, Paris, San Francisco, Tokyo and Washington DC. For more information, please go to <u>www.nature.com</u>.